Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Watkins

Showing results (731-740 of 775) with videos related to

Pageof 78
Sort By:
Nature Communications|October 17, 2022
Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for strokeLingyan Chen, James E Peters, Bram Prins, et al.
Cell Reports. Medicine|July 8, 2025
Activity-attenuated serum albumin-fused interleukin-33 suppresses experimental autoimmune encephalomyelitisErica Budina, Joseph W Reda, Shijie Cao, et al.
Plos One|December 1, 2020
Proactive prevention: Act now to disrupt the impending non-communicable disease crisis in low-burden populationsBenson Njuguna, Sara L Fletcher, Constantine Akwanalo, et al.
Journal of Lipid Research|August 5, 2004
Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene familyDouglas G Mashek, Karin E Bornfeldt, Rosalind A Coleman, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitorsRima S Al-awar, James E Ray, Kyle A Hecker, et al.
The Journal of Biological Chemistry|March 26, 2016
Receptor Activity-modifying Proteins 2 and 3 Generate Adrenomedullin Receptor Subtypes with Distinct Molecular PropertiesHarriet A Watkins, Madhuri Chakravarthy, Rekhati S Abhayawardana, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluationCarlos Jaramillo, J Eugenio de Diego, Chafiq Hamdouchi, et al.
Circulation. Population Health and Outcomes|May 1, 2026
Early Implementation and Clinical Outcomes of an Integrated Rheumatic Heart Disease Screening and Treatment Program in Northern UgandaJafesi Pulle, James Kayima, Nanhua Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|October 14, 2003
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitorsConcha Sanchez-Martinez, Chuan Shih, Margaret M Faul, et al.
The New England Journal of Medicine|August 24, 2017
Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015David A Watkins, Catherine O Johnson, Samantha M Colquhoun, et al.
Pageof 78

Showing results (731-740 of 775) with videos related to

Sort By:
Pageof 78
Nature Communications|October 17, 2022
Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for strokeLingyan Chen, James E Peters, Bram Prins, et al.
Cell Reports. Medicine|July 8, 2025
Activity-attenuated serum albumin-fused interleukin-33 suppresses experimental autoimmune encephalomyelitisErica Budina, Joseph W Reda, Shijie Cao, et al.
Plos One|December 1, 2020
Proactive prevention: Act now to disrupt the impending non-communicable disease crisis in low-burden populationsBenson Njuguna, Sara L Fletcher, Constantine Akwanalo, et al.
Journal of Lipid Research|August 5, 2004
Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene familyDouglas G Mashek, Karin E Bornfeldt, Rosalind A Coleman, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitorsRima S Al-awar, James E Ray, Kyle A Hecker, et al.
The Journal of Biological Chemistry|March 26, 2016
Receptor Activity-modifying Proteins 2 and 3 Generate Adrenomedullin Receptor Subtypes with Distinct Molecular PropertiesHarriet A Watkins, Madhuri Chakravarthy, Rekhati S Abhayawardana, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluationCarlos Jaramillo, J Eugenio de Diego, Chafiq Hamdouchi, et al.
Circulation. Population Health and Outcomes|May 1, 2026
Early Implementation and Clinical Outcomes of an Integrated Rheumatic Heart Disease Screening and Treatment Program in Northern UgandaJafesi Pulle, James Kayima, Nanhua Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|October 14, 2003
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitorsConcha Sanchez-Martinez, Chuan Shih, Margaret M Faul, et al.
The New England Journal of Medicine|August 24, 2017
Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015David A Watkins, Catherine O Johnson, Samantha M Colquhoun, et al.
Pageof 78